Document is current
Any future updates will be listed below
-
Authors
Lensen, Sarah http://orcid.org/0000-0002-1694-1142
Macnair, Archie http://orcid.org/0000-0001-5429-9114
Love, Sharon B. http://orcid.org/0000-0002-6695-5390
Yorke-Edwards, Victoria http://orcid.org/0000-0002-6465-7330
Noor, Nurulamin M. http://orcid.org/0000-0003-3426-6408
Martyn, Meredith http://orcid.org/0000-0002-2342-6771
Blenkinsop, Alexandra http://orcid.org/0000-0002-2328-8671
Diaz-Montana, Carlos http://orcid.org/0000-0001-9082-4596
Powell, Graham http://orcid.org/0000-0003-3840-2534
Williamson, Elizabeth http://orcid.org/0000-0001-6905-876X
Carpenter, James http://orcid.org/0000-0003-3890-6206
Sydes, Matthew R. http://orcid.org/0000-0002-9323-1371
-
Funding
Funding for this research was provided by:
HDRUK (UCL Account umber - 548519)
- License Information
-
More Information
Article History
Received: 6 January 2020
Accepted: 18 April 2020
First Online: 12 May 2020
Ethics approval and consent to participate
: These were not required as this was a review of RCTs accessing RCHD and no patient-level data were used.
: Not applicable.
: All authors have completed the International Committee of Medical Journal Editors uniform disclosure form at ExternalRef removed and declare a grant from HDR UK to support this project. MRS reports grants from Health Data Research UK during the conduct of the study, personal fees from Lilly Oncology and Janssen, and grants and non-financial support from Astellas, Clovis Oncology, Janssen, Novartis, Pfizer, and Sanofi-Aventis outside the submitted work. SLo reports travel and subsistence from Federal Drugs Agency outside the submitted work.
